News & Updates

Long-term benefits with molnupiravir modest at best in COVID-19 treatment
Long-term benefits with molnupiravir modest at best in COVID-19 treatment
24 Sep 2024 byJairia Dela Cruz

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

Long-term benefits with molnupiravir modest at best in COVID-19 treatment
24 Sep 2024
Surgery, mechanical aspiration do not prevent death in tricuspid valve infective endocarditis
Surgery, mechanical aspiration do not prevent death in tricuspid valve infective endocarditis
24 Sep 2024
What fuels flu, pneumococcal vaccine hesitancy in SG?
What fuels flu, pneumococcal vaccine hesitancy in SG?
23 Sep 2024 byJairia Dela Cruz

In Singapore, influenza and pneumococcal vaccination coverage remains stubbornly low. Results of two separate analysis of a cross-sectional survey shed light on this concerning trend, highlighting the roles of vaccine knowledge and attitude, healthcare professionals, and social support in influencing vaccination decisions.

What fuels flu, pneumococcal vaccine hesitancy in SG?
23 Sep 2024
COVID-19 variants carry no increased autoimmune sequelae risk
COVID-19 variants carry no increased autoimmune sequelae risk
16 Sep 2024 byJairia Dela Cruz

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

COVID-19 variants carry no increased autoimmune sequelae risk
16 Sep 2024
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
No benefit to SGLT2 inhibitor therapy in hospitalized COVID-19 patients
15 Sep 2024
Fewer CV events after COVID-19 vaccine-related myocarditis
Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024 byElvira Manzano

In a nationwide French cohort study, myocarditis attributed to COVID-19 mRNA vaccination causes fewer cardiovascular (CV) events at 18 months of follow-up than that attributed to SARS-CoV-2 infection or myocarditis of conventional aetiologies.

Fewer CV events after COVID-19 vaccine-related myocarditis
13 Sep 2024